Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Peptide Comparison

Argireline vs Pal-AHK

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Argireline and Pal-AHK share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Argireline has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Argireline's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Argireline

Cosmetic Clinical Studies

Pal-AHK

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Argireline Pal-AHK
Class Cosmetic peptide; SNAP-25 inhibitor Cosmetic lipopeptide (hair)
Drug class Dermatologic Dermatologic
Mechanism Mimics SNAP-25 N-terminus; inhibits neurotransmitter release at neuromuscular junction (topical) Palmitoyl-modified AHK for enhanced skin/scalp penetration; angiogenic signaling
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 3-10% Topical 0.1-1%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 92 indexed (PubMed 44 · CT 6 · EPMC 42) 4 indexed (PubMed 0 · CT 0 · EPMC 4)
Availability Cosmetic Cosmetic
Reported risks Limited depth vs Botox; possible irritation Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Argireline or Pal-AHK?

Argireline and Pal-AHK share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Argireline has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Argireline's evidence base is currently denser.

What is the difference between Argireline and Pal-AHK?

Argireline is classed as Cosmetic peptide; SNAP-25 inhibitor; Pal-AHK is classed as Cosmetic lipopeptide (hair). Reported mechanism: Argireline, Mimics SNAP-25 N-terminus; inhibits neurotransmitter release at neuromuscular junction (topical); Pal-AHK, Palmitoyl-modified AHK for enhanced skin/scalp penetration; angiogenic signaling. Reported half-life: Argireline, Topical; Pal-AHK, Topical. Routes in published studies: Argireline, Topical; Pal-AHK, Topical.

Which has stronger evidence, Argireline or Pal-AHK?

Argireline and Pal-AHK sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Argireline is graded Cosmetic Clinical Studies, with 6 cited sources on its reference page and 92 indexed studies. Pal-AHK is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 4 indexed studies.

Which is more accessible, Argireline or Pal-AHK?

Neither Argireline nor Pal-AHK is an FDA-approved drug. Catalog status: Argireline, Cosmetic; Pal-AHK, Cosmetic.

Are Argireline and Pal-AHK ever combined?

Argireline and Pal-AHK appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…